查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949353

全球大分子藥物原料藥CDMO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Large Molecule Drug Substance CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計大分子原料藥的CDMO市場將從2025年的228.8億美元成長到2034年的533.7億美元，2026年至2034年的複合年成長率為9.87%。

由於生物製藥日益複雜以及對創新治療方法的需求不斷成長，大分子原料藥的合約研發生產機構（CDMO）市場預計將顯著擴張。隨著製藥公司將重點轉向生物製藥，對專業化生產能力的需求變得至關重要。該市場的特點是從傳統的小分子藥物轉向大分子療法，包括單株抗體、重組蛋白和基因療法。這些產品的複雜性要求採用先進的生產流程、嚴格的品管和合規性——而這正是CDMO具有獨特優勢的領域。

此外，個人化醫療的興起正在推動對生物製藥療法的需求，進一步加速大分子藥物原料藥CDMO市場的成長。隨著醫療系統日益採用精準醫療方法，大規模生產客製化生物製藥的能力將成為製藥公司的關鍵差異化優勢。投資於一次性系統和連續生產等先進技術的CDMO可望獲得競爭優勢。此外，生物製藥公司與CDMO之間的策略聯盟將促進創新，加速新型治療方法的研發，確保市場保持活力並能回應不斷變化的醫療保健需求。

全球大分子原料原料藥生產力機構（CDMO）的發展趨勢也受到不斷變化的監管環境和永續性的永續發展意識的影響。隨著監管機構簡化生物製藥的核准流程，新治療方法的上市時間縮短，為CDMO創造了更靈活的營運環境。此外，將永續實踐融入生產流程不僅滿足監管要求，也符合消費者對環境友善醫療保健解決方案日益成長的需求。隨著市場的發展，那些優先考慮創新、合作和永續性的CDMO將在這個快速成長的產業中佔據有利地位，並取得成功。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球大分子藥物原料藥CDMO市場（依服務類型分類）

  • 市場分析、洞察與預測
  • 契約製造
  • 合約開發

5. 全球大分子藥物原料藥CDMO市場（依來源分類）

  • 市場分析、洞察與預測
  • 哺乳動物
  • 微生物來源
  • 其他

6. 全球大分子藥物原料藥CDMO市場（依最終用戶分類）

  • 市場分析、洞察與預測
  • 生技公司
  • CRO
  • 其他

7. 全球大分子藥物原料藥CDMO市場（依地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Eurofins Scientific
    • WuXi Biologics
    • Samsung Biologics
    • Catalent Inc
    • Rentschler Biopharma SE
    • AGC Biologics
    • Recipharm AB
    • Siegfried Holding AG
    • Boehringer Ingelheim
    • FUJIFILM Diosynth Biotechnologies
簡介目錄
Product Code: VMR112110346

The Large Molecule Drug Substance CDMO Market size is expected to reach USD 53.37 Billion in 2034 from USD 22.88 Billion (2025) growing at a CAGR of 9.87% during 2026-2034.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

  • Contract Manufacturing
  • Contract Development

By Source

  • Mammalian
  • Microbial
  • Others

By End-User

  • Biotech Companies
  • CRO
  • Other

COMPANIES PROFILED

  • Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent Inc, Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SERVICE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Service
  • 4.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Source
  • 5.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. CRO Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Service
    • 7.2.2 By Source
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Service
    • 7.3.2 By Source
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Service
    • 7.4.2 By Source
    • 7.4.3 By End-user
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Service
    • 7.5.2 By Source
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Service
    • 7.6.2 By Source
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Eurofins Scientific
    • 9.2.2 WuXi Biologics
    • 9.2.3 Samsung Biologics
    • 9.2.4 Catalent Inc
    • 9.2.5 Rentschler Biopharma SE
    • 9.2.6 AGC Biologics
    • 9.2.7 Recipharm AB
    • 9.2.8 Siegfried Holding AG
    • 9.2.9 Boehringer Ingelheim
    • 9.2.10 FUJIFILM Diosynth Biotechnologies